Anti-inflammatory immune skewing is atheroprotective: Apoe-/-fcγRIIb-/- mice develop fibrous carotid plaques

Journal of the American Heart Association

Volumn 3, Issue 6, 2014, Pages

  Harmon, Erin Y ^a   Fronhofer, Van ^a   Keller, Rebecca S ^a   Feustel, Paul J ^a   Zhu, Xinmei ^b   Xu, Hao ^a   Avram, Dorina ^a   Jones, David M ^a   Nagarajan, Shanmugam ^b   Lennartz, Michelle R ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Treg; Atherosclerosis; Carotid artery; FccR; M2; Macrophages

Indexed keywords

APOLIPOPROTEIN E; ARGINASE 1; FC RECEPTOR IIB; IMMUNOGLOBULIN G; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; ARG1 PROTEIN, MOUSE; ARGINASE; AUTACOID; CYTOKINE; FC RECEPTOR; FCGR2B PROTEIN, MOUSE; NOS2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; CAROTID ARTERY OBSTRUCTION; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DESCENDING AORTA; FOAM CELL; IN VITRO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; ACOUSTIC MICROSCOPY; ANIMAL; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; CAROTID STENOSIS; DEFICIENCY; DISEASE MODEL; ECHOGRAPHY; FIBROSIS; GENETICS; GENOTYPE; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; NECROSIS; PHENOTYPE;

ANIMALS; APOLIPOPROTEINS E; ARGINASE; CAROTID ARTERIES; CAROTID STENOSIS; CYTOKINES; DISEASE MODELS, ANIMAL; FIBROSIS; GENOTYPE; INFLAMMATION; INFLAMMATION MEDIATORS; MACROPHAGES; MALE; MICE, KNOCKOUT; MICROSCOPY, ACOUSTIC; NECROSIS; NITRIC OXIDE SYNTHASE TYPE II; PHENOTYPE; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, IGG; T-LYMPHOCYTES, REGULATORY;

EID: 84930579521     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.001232     Document Type: Article

References (46)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125:e2-e220.
2. Devuyst G, Karapanayiotides T, Ruchat P, Pusztaszeri M, Lobrinus JA, Jonasson L, Cuisinaire O, Kalangos A, Despland PA, Thiran JP, Bogousslavsky J. Ultrasound measurement of the fibrous cap in symptomatic and asymptomatic atheromatous carotid plaques. Circulation. 2005;111:2776-2782.
3. von der Thusen JH, van Berkel TJ, Biessen EA. Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein E-deficient and lowdensity lipoprotein receptor-deficient mice. Circulation. 2001;103:1164-1170.
4. Cheng C, van Haperen R, de Waard M, van Damme LC, Tempel D, Hanemaaijer L, van Cappellen GW, Bos J, Slager CJ, Duncker DJ, van der Steen AF, de Crom R, Krams R. Shear stress affects the intracellular distribution of eNOS: direct demonstration by a novel in vivo technique. Blood. 2005;106:3691-3698.
5. Cheng C, Tempel D, van Haperen R, van der Baan A, Grosveld F, Daemen MJ, Krams R, de Crom R. Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. Circulation. 2006;113:2744-2753.
6. Helderman F, Segers D, de Crom R, Hierck BP, Poelmann RE, Evans PC, Krams R. Effect of shear stress on vascular inflammation and plaque development. Curr Opin Lipidol. 2007;18:527-533.
7. Harmon EY, Fronhofer V, Keller RS, Feustel PJ, Brosnan MJ, von der Thüsen JH, Loegering DJ, Lennartz MR. Ultrasound biomicroscopy for longitudinal studies of carotid plaque development in mice: validation with histological endpoints. PLoS One. 2012;7:e29944.
8. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129-2138.
9. Lennartz MR, Aggarwal A, Michaud TM, Feustel PJ, Jones DM, Brosnan MJ, Keller RS, Loegering DJ, Kreienberg PB. Ligation of macrophage Fcγ receptors recapitulates the gene expression pattern of vulnerable human carotid plaques. PLoS One. 2011;6:e21803.
10. Ng HP, Burris RL, Nagarajan S. Attenuated atherosclerotic lesions in apoEFcgamma chain-deficient hyperlipidemic mouse model is associated with inhibition of Th17 cells and promotion of regulatory T cells. J Immunol. 2011;187:6082-6093.
11. Hernandez-Vargas P, Ortiz-Munoz G, Lopez-Franco O, Suzuki Y, Gallego-Delgado J, Sanjuan G, Lazaro A, Lopez-Parra V, Ortega L, Egido J, Gomez-Guerrero C. Fcgamma receptor deficiency confers protection against atherosclerosis in apolipoprotein E knockout mice. Circ Res. 2006;99:1188-1196.
12. Kelly JA, Griffin ME, Fava RA, Wood SG, Bessette KA, Miller ER, Huber SA, Binder CJ, Witztum JL, Morganelli PM. Inhibition of arterial lesion progression in CD16-deficient mice: evidence for altered immunity and the role of IL-10. Cardiovasc Res. 2010;85:224-231.
13. Mendez-Fernandez YV, Stevenson BG, Diehl CJ, Braun NA, Wade NS, Covarrubias R, van Leuven S, Witztum JL, Major AS. The inhibitory Fc [gamma]RIIb modulates the inflammatory response and influences atherosclerosis in male apoE-/-mice. Atherosclerosis. 2011;214:73-80.
14. Zhao M, Wigren M, Duner P, Kolbus D, Olofsson KE, Bjorkbacka H, Nilsson J, Fredrikson GN. Fc{gamma}RIIB inhibits the development of atherosclerosis in low-density lipoprotein receptor-deficient mice. J Immunol. 2010;184:2253-2260.
15. Gallo P, Goncalves R, Mosser DM. The influence of IgG density and macrophage Fc (gamma) receptor cross-linking on phagocytosis and IL-10 production. Immunol Lett. 2010;133:70-77.
16. Khallou-Laschet J, Varthaman A, Fornasa G, Compain C, Gaston AT, Clement M, Dussiot M, Levillain O, Graff-Dubois S, Nicoletti A, Caligiuri G. Macrophage plasticity in experimental atherosclerosis. PLoS One. 2010;5:e8852.
17. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677-686.
18. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12:204-212.
19. Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity. 2013; 38:1092-1104.
20. Seimon TA, Wang Y, Han S, Senokuchi T, Schrijvers DM, Kuriakose G, Tall AR, Tabas IA. Macrophage deficiency of p38alpha MAPK promotes apoptosis and plaque necrosis in advanced atherosclerotic lesions in mice. J Clin Invest. 2009;119:886-898.
21. Kuchibhotla S, Vanegas D, Kennedy DJ, Guy E, Nimako G, Morton RE, Febbraio M. Absence of CD36 protects against atherosclerosis in ApoE knock-out mice with no additional protection provided by absence of scavenger receptor A I/II. Cardiovasc Res. 2008;78:185-196.
22. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol. 1995;15:1512-1531.
23. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145:341-355.
24. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
25. Chinetti-Gbaguidi G, Baron M, Bouhlel MA, Vanhoutte J, Copin C, Sebti Y, Derudas B, Mayi T, Bories G, Tailleux A, Haulon S, Zawadzki C, Jude B, Staels B. Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPAR{gamma} and LXRα Pathways. Circ Res. 2011;108:985-995.
26. Boyle JJ, Johns M, Kampfer T, Nguyen AT, Game L, Schaer DJ, Mason JC, Haskard DO. Activating transcription factor 1 directs Mhem atheroprotective macrophages through coordinated iron handling and foam cell protection. Circ Res. 2012;110:20-33.
27. Mantovani A, Garlanda C, Locati M. Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol. 2009;29:1419-1423.
28. Liu Y, Li D, Chen J, Xie J, Bandyopadhyay S, Zhang D, Nemarkommula AR, Liu H, Mehta JL, Hermonat PL. Inhibition of atherogenesis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10. Atherosclerosis. 2006;188:19-27.
29. Potteaux S, Esposito B, van Oostrom O, Brun V, Ardouin P, Groux H, Tedgui A, Mallat Z. Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol. 2004;24:1474-1478.
30. Caligiuri G, Rudling M, Ollivier V, Jacob MP, Michel JB, Hansson GK, Nicoletti A. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and lowdensity lipoproteins in apolipoprotein E knockout mice. Mol Med. 2003;9:10-17.
31. Nimmerjahn F, Ravetch JV, Frederick WA. Fc-receptors as regulators of immunity. In: Frederick ALT, ed. Advances in Immunology. Waltham, MA: Academic Press; 2007:179-204.
32. Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem. 2001;276:16683-16689.
33. Lee JY, Ye J, Gao Z, Youn HS, Lee WH, Zhao L, Sizemore N, Hwang DH. Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J Biol Chem. 2003;278:37041-37051.
34. Larsen EC, Ueyama T, Brannock PM, Shirai Y, Saito N, Larsson C, Loegering D, Weber PB, Lennartz MR. A role for PKC-varepsilon in FcgammaR-mediated phagocytosis by RAW 264.7 cells. J Cell Biol. 2002;159:939-944.
35. Klingenberg R, Gerdes N, Badeau RM, Gistera A, Strodthoff D, Ketelhuth DF, Lundberg AM, Rudling M, Nilsson SK, Olivecrona G, Zoller S, Lohmann C, Luscher TF, Jauhiainen M, Sparwasser T, Hansson GK. Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis. J Clin Invest. 2013;123:1323-1334.
36. Mor A, Planer D, Luboshits G, Afek A, Metzger S, Chajek-Shaul T, Keren G, George J. Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:893-900.
37. George J, Schwartzenberg S, Medvedovsky D, Jonas M, Charach G, Afek A, Shamiss A. Regulatory T cells and IL-10 levels are reduced in patients with vulnerable coronary plaques. Atherosclerosis. 2012;222:519-523.
38. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med. 2002;195:1653-1659.
39. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood. 2006;108:1435-1440.
40. Wang Y, Su MA, Wan YY. An essential role of the transcription factor GATA-3 for the function of regulatory T cells. Immunity. 2011;35:337-348.
41. Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity. 2006;24:19-28.
42. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313:670-673.
43. Anthony RM, Ravetch JV. A novel role for the IgG Fc glycan: the antiinflammatory activity of sialylated IgG Fcs. J Clin Immunol. 2010;30(suppl 1): S9-S14.
44. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature. 2011;475:110-113.
45. De Groot AS, Moise L, McMurry JA, Wambre E, Van Overtvelt L, Moingeon P, Scott DW, Martin W. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood. 2008;112:3303-3311.
46. Boross P, Arandhara VL, Martin-Ramirez J, Santiago-Raber ML, Carlucci F, Flierman R, van der Kaa J, Breukel C, Claassens JW, Camps M, Lubberts E, Salvatori D, Rastaldi MP, Ossendorp F, Daha MR, Cook HT, Izui S, Botto M, Verbeek JS. The inhibiting Fc receptor for IgG, FcgammaRIIB, is a modifier of autoimmune susceptibility. J Immunol. 2011;187:1304-1313.